Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy

Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II dose (RP2D), and dose-limiting toxicities (DLTs...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Park, Haeseong, Garrido-Laguna, Ignacio, Naing, Aung, Fu, Siqing, Falchook, Gerald S., Piha-Paul, Sarina A., Wheler, Jennifer J., Hong, David S., Tsimberidou, Apostolia M., Subbiah, Vivek, Zinner, Ralph G., Kaseb, Ahmed O., Patel, Shreyaskumar, Fanale, Michelle A., Velez-Bravo, Vivianne M., Meric-Bernstam, Funda, Kurzrock, Razelle, Janku, Filip
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2016
Schlagworte:
Clinical Research Paper
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5341894/
https://ncbi.nlm.nih.gov/pubmed/27589687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11750
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge